Wall Street Zen cut shares of aTyr Pharma (NASDAQ:ATYR – Free Report) from a hold rating to a strong sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.
Several other research analysts also recently commented on the stock. Freedom Broker downgraded shares of aTyr Pharma from a “strong-buy” rating to a “hold” rating in a report on Friday, November 6th. Royal Bank Of Canada reduced their target price on aTyr Pharma to $6.00 and set a “sector perform” rating on the stock in a report on Friday, November 6th. Weiss Ratings downgraded aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. Finally, Wells Fargo & Company boosted their target price on aTyr Pharma from $1.00 to $4.00 and gave the stock an “equal weight” rating in a research report on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $5.00.
Get Our Latest Research Report on ATYR
aTyr Pharma Stock Performance
Shares of NASDAQ:ATYR opened at $5.24 on Friday. The firm has a fifty day moving average price of $10.03 and a 200 day moving average price of $22.93. aTyr Pharma has a fifty-two week low of $4.07 and a fifty-two week high of $44.40.
aTyr Pharma (NASDAQ:ATYR – Get Free Report) last announced its quarterly earnings results on Friday, November 6th. The company reported ($7.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($4.00) by ($3.43). Research analysts expect that aTyr Pharma will post -22.96 earnings per share for the current fiscal year.
Institutional Investors Weigh In On aTyr Pharma
A hedge fund recently bought a new position in aTyr Pharma stock. Renaissance Technologies LLC purchased a new stake in shares of aTyr Pharma, Inc. (NASDAQ:ATYR – Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 40,522 shares of the company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.
aTyr Pharma Company Profile
aTyr Pharma is a clinical-stage biotechnology company focused on developing medicines based on the extracellular biology of tRNA synthetases, a family of proteins involved in cellular processes. The company is headquartered in San Diego, California. Its lead drug candidate, efzofitimod, is an immunomodulator being studied for pulmonary sarcoidosis and other interstitial lung diseases. The candidate is designed to act through neuropilin-2, a receptor involved in immune regulation. aTyr’s research programs draw on its work in tRNA synthetase biology, with the broader goal of developing treatments for inflammatory and fibrotic conditions.
Further Reading
- Five stocks we like better than aTyr Pharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
